Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.

Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.

Item
http://www.wikidata.org/entity/Q34000731
Pseudomonas aeruginosa ventilator-associated pneumonia managementVaccines for Pseudomonas aeruginosa: a long and winding roadIdentification of OprF as a complement component C3 binding acceptor molecule on the surface of Pseudomonas aeruginosaOral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model.Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant.Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccineProtection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase.Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosaA randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF.A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients.Recent developments for Pseudomonas vaccines.Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa.Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study.RGD capsid modification enhances mucosal protective immunity of a non-human primate adenovirus vector expressing Pseudomonas aeruginosa OprF.
P2860

Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.

Item
http://www.wikidata.org/entity/Q34000731
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Safety and immunogenicity of a ...... I vaccine in human volunteers.
@ast
Safety and immunogenicity of a ...... I vaccine in human volunteers.
@en
Safety and immunogenicity of a ...... I vaccine in human volunteers.
@nl
type
label
Safety and immunogenicity of a ...... I vaccine in human volunteers.
@ast
Safety and immunogenicity of a ...... I vaccine in human volunteers.
@en
Safety and immunogenicity of a ...... I vaccine in human volunteers.
@nl
prefLabel
Safety and immunogenicity of a ...... I vaccine in human volunteers.
@ast
Safety and immunogenicity of a ...... I vaccine in human volunteers.
@en
Safety and immunogenicity of a ...... I vaccine in human volunteers.
@nl
P1433
P1476
P2093
P2860
P304
P31
P407
P433
P478
P577
P698
P932
P1433
P1476
Safety and immunogenicity of a ...... -I vaccine in human volunteers
@en
P2093
P2860
P304
P31
P407
P433
P478
P577
P698
P932